Milestones

Milestones

Lysistech GmbH
  • 2011

  • Q1

    Lysistech® is founded as an LLC in Stuttgart Germany with a focus on laser-therapy and supporting equipment in minimally invasive surgery

  • Q2

    The laser treatment portfolio is expanded into orthopaedics


    Our signature STRONg in SPINE PLDD treatment set is developed and introduced in a joint effort with our German partners in laser-fibre technologies

  • 2012

  • Q2

    Our laser treatment portfolio is expanded into phlebology


    Our signature SoFT in VEIN varicose-treatment set is developed and introduced in a joint effort with our partners in laser-fibre technologies

  • 2014

  • Q4

    The ideation phase for the introduction of radio-frequency (RF)-therapies begins

  • 2015

  • Q2

    Lysistech® moves HQ into its fully-owned building in the historic centre of Brunswick with new office and storage capacities


    Our operational team expands with new faces specialised in technical support, field application and sales

  • Q3

    Our first RF-plasma electrodes with the coblation technology enter the concept phase


    The in-house testing phase of our nucleoplasty prototype electrodes is successfully completed

  • Q4
    Clinical testing by independent institutions approve our nucleoplasty electrodes for test production and limited release into the German market


    Our laser therapy portfolio expands into proctology

  • 2016

  • Q1

    Cervical and lumbar nucleoplasty solutions formally enter our neuro-orthopaedic coblation portfolio

  • Q2

    First Lysistech® clients opt-in to expand their neuro-orthopaedic treatment options with our nucleoplasty treatments

  • Q3

    Our Coblation division prepares for the introduction of Sport Medicine (arthroscopic) surgical solutions


    The first arthroscopic Coblation electrode is successfully test in-house

  • Q4

    Our engineering and clinical applications team employs new specialists to expand R&D capacities

  • 2017

  • Q1

    MasterVac und Sinew50 electrodes are commissioned for market release in our Sports Medicine division


    Preparations for corporate restructuring are initiated to facilitate setup of internal production capacities and support global expansion efforts


    Initial market access plans for the Russia expansion are drafted


    CE and ISO-13485 certification process in accordance with the EEC MDR directive is initiated

  • Q2

    Storage facilities, IT-infrastructures and QM-Systems are upgraded and implemented


    First production and R&D capacities are activated both within and outside of Germany

  • Q3

    Lysistech® passes its first ISO-13485 Audit


    Fully self-developed medical devices gain CE-approval

  • Q4

    Lysistech® officially becomes a full-fledged medical device manufacturer

  • 2018

  • Q1

    Lysistech® takes over the distribution of its products within the DACH-region

  • 2019

  • Q1

    Mrs. Heidi Fischer, formerly at ArthroCare (Smith&Nephew PLC), is appointed as acting CEO of Lysistech LLC


    Lysistech® moves HQ, including the sales department, to Gräfelfing (Munich), Bavaria


    Brunswick remains as the central storage facility and contact centre for clients in Northern Germany